This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of engineered enzymes that can be activated to perform targeted modifications of cellular proteins. The $1,602,000 award to the Dana-Farber Cancer Institute, Inc. (DFCI) will fund research to design and apply novel autoinhibited enzymes that can toggle between inactive and active conformations in response to specific molecular cues. This work aims to create synthetic enzymes capable of controlling protein degradation, constructing biosensors, and rewriting cell signaling pathways - capabilities that differ from endogenous enzymes and enable new possibilities for basic research and biotechnology applications. The project will run from September 1, 2023 through August 31, 2026.
Generated 7/16/24, 5:40 AM